Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response.

about

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response.

Item

http://www.wikidata.org/entity/Q37389601

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Quantification of epidermal gr ...... inhibitor treatment response.

@en

Quantification of epidermal growth factor receptor

@nl

type

Item

label

Quantification of epidermal gr ...... inhibitor treatment response.

@en

Quantification of epidermal growth factor receptor

@nl

prefLabel

Quantification of epidermal gr ...... inhibitor treatment response.

@en

Quantification of epidermal growth factor receptor

@nl

P1476

Quantification of epidermal gr ...... inhibitor treatment response.

@en

P2093

Cheol-Kyu Park

http://www.w3.org/2001/XMLSchema#string

Ha Young Park

http://www.w3.org/2001/XMLSchema#string

Hong-Jun Shin

http://www.w3.org/2001/XMLSchema#string

Hyung Joo Oh

http://www.w3.org/2001/XMLSchema#string

In-Jae Oh

http://www.w3.org/2001/XMLSchema#string

Jung-Hwan Lim

http://www.w3.org/2001/XMLSchema#string

Ki-Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Sung-Chul Lim

http://www.w3.org/2001/XMLSchema#string

Tae-Ok Kim

http://www.w3.org/2001/XMLSchema#string

Yong-Soo Kwon

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of lung cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

P304

639-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12378

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27755804

http://www.w3.org/2001/XMLSchema#string

P932

5093171

http://www.w3.org/2001/XMLSchema#string